Professional Documents
Culture Documents
Date: Time: Contact: Monday, 6 June 2011 11:00 Press Office 020 3080 7564/7651 Out of hours 07770 446 189 press.office@mhra.gsi.gov.uk
_________________________________________________________________
Notes to Editor 1. There are two different strengths of liquid paracetamol formulations for children and the changes apply to both: Infant paracetamol suspension (120 mg/5ml) CURRENT DOSE UPCOMING DOSE
AGE
2.5 ml
2.5 ml
5 to 10 ml
4 times
6 24 months
5 ml
4 times
2 4 years 4 6 years Paracetamol six plus suspension (240/250 mg/5ml) CURRENT DOSE How often (in 24 hours) 5 to 10 ml 4 times
7.5 ml 10 ml
4 times 4 times
AGE
AGE
UPCOMING DOSE
6 12 years
5 ml 7.5 ml 10 ml
2.
Parents and carers can safely supply paracetamol to children by following the medicines full label directions as usual. For paracetamol supplied on prescription, the label the pharmacists put on the bottle will give the new doses; for over-the-counter medicines, parents should follow the dosage on the label. When the new packs are in stock, parents or carers with any questions can always ask a pharmacist or healthcare professional, or ring NHS Direct for more information. For safety, all medicines for children will be supplied with a dosing device, such as a plastic spoon, cap or measuring syringe, which parents and carers should always use to ensure uniform doses are provided. It is also important to shake the bottle vigorously before measuring the required dose, to ensure the paracetamol is divided equally into each dose. In the UK, all patient information leaflets have been tested to ensure they are clear and understandable. At the MHRA, we continually monitor the safety, quality and efficacy of all medicines, so that prompt action can be taken to protect people when appropriate.
3.
The MHRA and Commission for Human Medicines (CHM) continue to monitor closely the safety of paracetamol, as well as all marketed drugs. 5. The MHRA is the government agency responsible for ensuring that medicines and medical devices work, and are acceptably safe. No product is risk-free. Underpinning all our work lie robust and fact-based judgements to ensure that the benefits to patients and the public justify the risks. We keep watch over medicines and devices, and take any necessary action to protect the public promptly if there is a problem. We encourage everyone the public and healthcare professionals as well as the industry to tell us about any problems with a medicine or medical device, so that we can investigate and take any necessary action. www.mhra.gov.uk